DiaMedica Therapeutics (DMAC) EBT Margin (2018)
DiaMedica Therapeutics' (DMAC) quarterly EBT Margin came in at 266.0% in Q3 2018.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) EBT Margin (2018) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported EBT Margin for 1 consecutive years, with 266.0% the latest figure, recorded in Q3 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.68 Bn | 193.69 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 178.73 Bn | 175.55 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 131.05 Bn | 123.20 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.79 Bn | 73.80 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.99 Bn | 55.81 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 53.41 Bn | 48.27 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.41 Bn | 30.10 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.72 Bn | 30.43 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.53 Bn | 29.53 Bn | 1.16 Mn | -20,427.46% |
| 10 | DiaMedica Therapeutics | 351.39 Mn | 351.39 Mn | - | - |